Soft Tissue Sarcoma - Pipeline Insight, 2025

This “Soft Tissue Sarcoma - Pipeline Insight, 2025” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Soft Tissue Sarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Soft Tissue Sarcoma: Understanding

Soft Tissue Sarcoma: Overview

Soft tissue sarcomas (STS) are a diverse group of malignant tumors that originate in the soft tissues of the body, including muscles, fat, blood vessels, nerves, tendons, and the lining of the joints. They are relatively rare, accounting for less than 1% of all adult cancers but are more common in children, where they represent about 7% of cancers. There are over 50 different subtypes of soft tissue sarcomas, each with distinct characteristics and behaviors. These tumors can develop anywhere in the body but are most frequently found in the arms, legs, and abdomen. The signs and symptoms of soft tissue sarcomas vary widely depending on the tumor's size, location, and subtype. In the early stages, these tumors often do not cause any symptoms, making them difficult to detect. As they grow, symptoms may include a noticeable lump or swelling, which may or may not be painful. If the tumor presses on nerves or muscles, it can cause pain or soreness. In the case of abdominal sarcomas, symptoms might include pain, a feeling of fullness, or digestive issues. Advanced stages can lead to systemic symptoms like weight loss and fatigue.

The exact cause of most soft tissue sarcomas is unknown. However, several risk factors have been identified, including genetic predispositions (such as familial cancer syndromes like Li-Fraumeni syndrome), exposure to certain chemicals (like herbicides and dioxins), and prior radiation therapy for other cancers. At the molecular level, many soft tissue sarcomas are associated with specific genetic mutations and chromosomal translocations that disrupt normal cell growth and division, leading to uncontrolled proliferation of cells. Diagnosis of soft tissue sarcoma typically involves a combination of imaging studies and biopsy. Imaging techniques such as MRI, CT scans, and PET scans are used to determine the tumor's size, location, and extent of spread. A biopsy, where a tissue sample is taken and examined under a microscope, is essential to confirm the diagnosis and to identify the specific type of sarcoma. Molecular genetic testing may also be performed to detect specific genetic abnormalities that can aid in diagnosis and guide treatment decisions.

Treatment for soft tissue sarcoma depends on the type, size, location, and stage of the tumor, as well as the patient's overall health. The primary treatment is usually surgical removal of the tumor, often followed by radiation therapy to eliminate any remaining cancer cells. In some cases, chemotherapy is used, especially for high-grade or metastatic sarcomas. Newer treatments, such as targeted therapies and immunotherapy, are also being explored and have shown promise in certain subtypes of soft tissue sarcomas. Multidisciplinary care involving oncologists, surgeons, radiologists, and pathologists is crucial for optimizing treatment outcomes and managing this complex disease.

"Soft Tissue Sarcoma - Pipeline Insight, 2025" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Soft Tissue Sarcoma pipeline landscape is provided which includes the disease overview and Soft Tissue Sarcoma treatment guidelines. The assessment part of the report embraces, in depth Soft Tissue Sarcoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Soft Tissue Sarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Soft Tissue Sarcoma R&D. The therapies under development are focused on novel approaches to treat/improve Soft Tissue Sarcoma.

Soft Tissue Sarcoma Emerging Drugs Chapters

This segment of the Soft Tissue Sarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Soft Tissue Sarcoma Emerging Drugs

Fibronum + Doxorubicin: Philogen S.p.A.

Fibromun (L19TNF) is a fully-human immunomodulatory product consisting of the L19 antibody and TNF (a strong pro-inflammatory cytokine). (Recombinant TNF has so far been approved only for certain clinical applications.) The fusion of TNF to the L19 antibody specific to the EDB domain of fibronectin results in a tumor-targeted product, which selectively localizes at the site of disease, while sparing healthy organs. Fibromun has shown potent anti-tumor activity, both as single agent and in combination with other drugs, in several immunocompetent preclinical models inducing in most cases long-lasting complete responses. Currently, the drug is in Phase III stage of its development for the treatment of Soft Tissue Sarcoma.

• Chiauranib: Chipscreen Biosciences, Ltd

Chiauranib, a highly selective Aurora B/VEGFR/PDGFR /c-Kit/CSF1R inhibitor, was developed by Chipscreen Biosciences specifically to address drug resistance. Chiauranib exerts a comprehensive anti-tumor effect by a triple-pathway mechanism that simultaneously inhibits tumor angiogenesis, prevents tumor cell mitosis, and modulates the tumor microenvironment. With a favorable safety profile, Chiauranib has outperformed drugs with a similar mechanism in its pharmacodynamic activity in animal studies.Currently, the drug is in Phase II stage of its development for the treatment of Soft Tissue Sarcoma.

LVGN6051 and Anlotinib: Lyvgen Biopharma Holdings Limited

Exlinkibart (LVGN6051) is a Anti-CD137/4-1BB agonistic monoclonal antibody and xLinkAb conditional 4-1BB agonistic monoclonal antibody with selective Fcγ-receptor IIB binding for targeted immune activation in the tumor microenvironment. LVGN6051 has achieved RP2D of 4 mg/kg Q3W, showing desirable PK and PD properties, acceptable safety profile and durable objective responses in heavily pre-treated patients with various solid tumors. Upon administration, anti-CD137 agonistic antibody LVGN6051 binds to and activates CD137 expressed on a variety of leukocyte subsets including activated T lymphocytes and natural killer (NK) cells. This enhances CD137-mediated signaling, induces cytokine production and promotes T-cell mediated anti-tumor immune responses. Registration clinical trials of exlinkibart in melanoma, sarcoma and head and neck cancers are planned. Currently, the drug is in Phase I/II stage of its development for the treatment of Soft Tissue Sarcoma.

Soft Tissue Sarcoma: Therapeutic Assessment

This segment of the report provides insights about the different Soft Tissue Sarcoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Soft Tissue Sarcoma

• There are approx. 70+ key companies which are developing the therapies for Soft Tissue Sarcoma. The companies which have their Soft Tissue Sarcoma drug candidates in the most advanced stage, i.e. phase III include, Philogen S.p.A.

Phases

The report covers around 75+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Soft Tissue Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Soft Tissue Sarcoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Soft Tissue Sarcoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Soft Tissue Sarcoma drugs.

Soft Tissue Sarcoma Report Insights

• Soft Tissue Sarcoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Soft Tissue Sarcoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Soft Tissue Sarcoma drugs?
• How many Soft Tissue Sarcoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Soft Tissue Sarcoma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Soft Tissue Sarcoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Soft Tissue Sarcoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Philogen S.p.A.
• Chipscreen Biosciences, Ltd
• Lyvgen Biopharma Holdings Limited
• Advenchen Laboratories, LLC
• OncoTherapy Science, Inc
• Philogen
• Washington University School of Medicine
• Sun Yat-sen University
• QBiotics Group Limited
• Thermosome GmbH
• Intensity Therapeutics, Inc.
• Centre Leon Berard
• Institut Claudius Regaud
• Base Therapeutics

Key Products

• Fibronum + Doxorubicin: P
• Chiauranib
• LVGN6051 and Anlotinib
• AL3818
• OTSA101-DTPA-111In
• L19 TNF
• ADI PEG20
• NY-ESO-1
• Tigilanol Tiglate
• DPPG2-TSL-DOX
• INT230-6
• Pazopanib
• SBRT + MEDI5752
• NK510

This product will be delivered within 3-5 business days.